LONDON - Celltech Group plc failed to reach the primary endpoint in Phase III trials of CDP 571, a humanized antibody for the treatment of Crohn's disease, leaving the future of the compound hanging on discussions with regulators to see if approval can be granted for the management of disease flares.(BioWorld International) Read More
